• News
  • ATRIVA scientists present MEK inhibitor technology at International Conference of Antiviral Research in Atlanta

Atriva Therapeutics takes part in four conferences in the upcoming months

Dr. Rainer Lichtenberger, CEO of Atriva, will represent the Company and will be available for networking and one-on-one meetings at the following events:

 

12th Annual International Partnering Conference BioPharm America

September 11th – 12th, 2019, Boston Convention & Exhibition Center, Boston, MA, USA
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation on September 12th, 3:00 – 3:10 pm EST.
ebdgroup.knect365.com/biopharm-america

 

19th Annual Biotech in Europe Forum (Sachs Conference)

September 25th – 26th, 2019, Congress Center Basel, Switzerland
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation on September 25th, 12:20 CET. Dr. Lichtenberger will also participate in the “Vaccines & Infectious Disease Panel” on September 25th, 17:05 CET.
www.sachsforum.com/bef19-about.html

 

25th Annual International Partnering Conference BIO-Europe®

November 11th – 13th, 2019, Hamburg Messe, Hamburg, Germany
Dr. Rainer Lichtenberger, CEO of Atriva, will give a Company Presentation.
ebdgroup.knect365.com/bioeurope

 

6th China Healthcare Summit 2019

November 18th – 20th, 2019, Jing An Shangri-La, Shanghai, China
www.biocentury.com/conferences/china-healthcare-summit-2019

 

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different respiratory viral infections. The lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development in a Phase I trial to evaluate safety and tolerability in healthy subjects. The Company owns seven broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2039. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

For further information, please visit www.atriva-therapeutics.com or see our LinkedIn profile  Atriva Therapeutics GmbH.

Contact:

Atriva Therapeutics GmbH
Dr. Rainer Lichtenberger, CEO
phone: +49 7071 859 7673
mobile: +49 173 743 1897
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media and Investor Relations:

MC Services AG
Raimund Gabriel / Eva Bauer
phone: +49 (0)89 21022880
This email address is being protected from spambots. You need JavaScript enabled to view it.

Address

Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.
Data Protection Rules I Agree